New gene editing technologies have energized the science of drug discovery and sparked a wave of startups. With the advent of CRISPR/Cas9 systems, a researcher can find an active nuclease on virtually any region of the genome, greatly reducing the time needed to develop novel therapies to treat a wide range of diseases.
But increased choice can lead to problems in building a cell line model yielding the best results. In the first presentation, we’ll address common real-world challenges in cell line engineering and explore methods to avoid the pitfalls.
Mark Your Calendars